RxDoctor Payments Data

Ashley Scaglione, PA

Medical · Hillsboro, MONPI 1538618285

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.9% of the total across 389 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 46 manufacturers reported payments, led by AbbVie at 45.0% of the total. Among medical clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,148in general payments, 2019–2025

Across 389 payments — averaging $18.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Lilly USA, LLC$553
  • Novo Nordisk$486
  • AstraZeneca$334
  • GSK$249
  • Pfizer$197
  • plus $2K from 40 others

What the payments were for

  • Food & beverage$7,07199%
  • Education$771%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,148 in reported general payments places this provider in the 90th percentile of 198 medical providers in Missouri.

See all medical providers in Missouri

Medicare billing

Part B allowed, 2024
$21,691
Medicare patients
92
Services billed
421

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide52$55,325
OzempicSemaglutide17$20,038
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$16,781
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$6,356
Baclofen22$2,337
Albuterol Sulfate HfaAlbuterol Sulfate57$1,514
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine23$1,376
Omeprazole59$1,161
Metoprolol Succinate69$1,072
Gabapentin63$821
Roflumilast11$731
Ventolin HfaAlbuterol Sulfate11$594
Atorvastatin Calcium79$575
Levothyroxine Sodium77$552
Losartan Potassium65$523

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$553$55,32552 claims
Novo NordiskOzempic$486$20,03817 claims
GSKTrelegy Ellipta$249$16,78126 claims
Almatica Pharma LLCSertraline Hcl$23$21142 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 198 medical providers in Missouri.

Other medical in Hillsboro

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →